Trastuzumab/Pertuzumab HercepTest companion diagnostic - Dako

Drug Profile

Trastuzumab/Pertuzumab HercepTest companion diagnostic - Dako

Alternative Names: Dako anti-her2 ihc system; HercepTest; Pertuzumab companion diagnostic - HercepTest - Dako; Trastuzumab companion diagnostic - HercepTest - Dako; Trastuzumab emtansine companion diagnostic - HercepTest - Dako

Latest Information Update: 28 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dako A/S
  • Class Diagnostic agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer

Most Recent Events

  • 21 Jun 2012 Dako A/S has been acquired by Agilent Technologies
  • 21 Oct 2010 Launched for Gastric cancer (Diagnosis) in USA (unspecified route)
  • 21 Oct 2010 Registered for Gastric cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top